U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07476001) titled 'Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC' on March 12.
Brief Summary: The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.5 months.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Metastatic Castration-resistant Prostate Cancer
Intervention:
DRUG: Testosterone cypionate (Tc)
IM injection of Tc at 400 mg (Tc400) every 28 da...